ArticleFrontiers in endocrinology2025
Innovative molecular targets for combatting metastasis in adrenocortical carcinoma.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastasis in adrenocortical carcinoma (ACC) presents a formidable clinical challenge, with limited insights into its underlying mechanisms and few effective treatment options. This study aimed to identify molecular markers associated with metastasis in adult ACC and to explore novel therapeutic approaches. Methods: RNA sequencing data from 74 adult ACC patients were analyzed using bioinformatics approaches, including weighted gene co-expression network analysis (WGCNA) and differential gene expression analysis. Functional pathway enrichment analyses were conducted to identify metastasis-associated genes and to explore key biological pathways contributing to metastatic progression. Candidate genes were selected based on their statistical significance, prognostic relevance, and involvement in metastatic processes. Results: Seven hub genes were identified as significantly associated with metastasis and poor prognosis in ACC patients. These genes were enriched in pathways critical to tumor progression, such as mismatch repair, nucleotide excision repair, and cell cycle regulation. High expression levels of these genes correlated with reduced overall survival. Importantly, potential therapeutic agents targeting these molecular drivers were identified, offering promising, lower-toxicity options for treating metastatic ACC. Conclusion: The molecular markers identified in this study offer valuable insights into the mechanisms underlying ACC metastasis and represent promising therapeutic targets, providing a foundation for developing improved treatment strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.